Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Category Archives: Immune Therapy
Cryoablation Immuno Therapy
Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease. Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- … Continue reading
Prostvac Vaccination for Localized Prostate Cancer Disease
Prostvac in Preventing Disease Progression in Patients with Localized Cancer Undergoing Active Surveillance. What is unique about this vaccine study , is the fact that it is given to patients with localized disease. Practically, the patient gets a series of vaccination … Continue reading
New Prostate Cancer Immunotherapy- Prostvac
Dr. Barken introduces the New Prostate Cancer Immune Therapy for earlier stages of Prostate Cancer. Please watch the video below and see what he learned at the National Cancer Institute recent conference mentioned above. Dr. James Gulley explains the Prostvac … Continue reading
Posted in Clinical Trials, Immune Therapy, Prostate Cancer, PSA, Treatments for Prostate Cancer
Tagged PSA Only disease
Leave a comment
Enzalutamide and Prostvac for patients with PSA only disease after primary treatment
This very significant development could become the standard treatment for prostate cancer in the future. Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov Identifier: NCT01875250
Sexual Funcation, Immune System, Choline 11 PET scan, Multi Parametric MRI and Decision Making Model for Prostate Cancer Disease
Click here to view your video
Dr. Mark Scholz discusses PCRI Conference
Dr. Israel Barken from the Prostate Cancer Research and Education Foundation, interviews Dr. Mark Scholz from Prostate Oncology Specialists in Marina Del Rey , California